Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension.

Trial Profile

Real Life Dosing Regimen of Remicade in Austria in Crohn's Disease - Program Extension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Sponsors Merck & Co; Schering-Plough
  • Most Recent Events

    • 25 Oct 2011 Actual patient number is 348 as reported by ClinicalTrials.gov.
    • 09 Sep 2010 Actual end date Jul 2010 added as reported by ClinicalTrials.gov.
    • 09 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top